Scalper1 News
Recent IPO Inovalon (INOV) was trading down as a passel of analysts issued mixed initiation reports Monday. As the underwriters’ quiet period ended following the company’s Feb. 11 IPO, their analysts were split between buy and neutral ratings. On the bull side, Robert W. Baird analyst Matthew Gillmor cited the uniqueness of Inovalon’s offering, deploying Big Data to help health care providers analyze risk and quality-management issues. “INOV’s Scalper1 News
Scalper1 News